Latest Licensing News

Avenira Limited has made significant strides in developing its Wonarah Phosphate Project, bolstered by strategic operational appointments and advancing infrastructure plans. Meanwhile, exploration at the Jundee South Gold Project is set to commence in 2026 amid ongoing regulatory challenges.

Gold Hydrogen Limited has reported successful drilling results confirming high-purity Natural Hydrogen and Helium at its Ramsay Project in South Australia, setting the stage for commercial pilot testing and green methanol development.

Far East Gold’s December quarter report highlights significant high-grade gold discoveries at its Idenburg Project and a key regulatory approval that paves the way for accelerated development.

Mesoblast Limited reported a 60% jump in Ryoncil sales to US$35 million for the December quarter, alongside securing a US$125 million credit facility that enhances its financial flexibility and supports ongoing clinical development.

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.

Mayne Pharma delivered a robust FY25 performance with a 105% surge in underlying EBITDA and launched key dermatology products as it outlines a strategic growth path for FY26.

Dimerix Limited has completed recruitment for its pivotal ACTION3 Phase 3 trial targeting a rare kidney disease, secured positive FDA feedback on trial endpoints, and reported a solid cash position of AU$38.5 million at the end of 2025.

Sunrise Energy Metals advances its Syerston Scandium Project with a robust updated Ore Reserve supporting a 32-year mine life, alongside significant financing commitments and a strategic offtake option with Lockheed Martin.

Equatorial Resources has completed the final hearing in its high-stakes arbitration against the Republic of Congo and is pursuing clarity on permit cancellations in Guinea, all while maintaining a solid cash reserve.

Racura Oncology reported a transformative quarter with key scientific discoveries, expanded clinical programs, and a robust cash position of $20.94 million, setting the stage for pivotal cancer trials in 2026.

Arovella Therapeutics has secured a crucial regulatory nod from the U.S. FDA, allowing its lead CAR-iNKT cell therapy, ALA-101, to enter first-in-human clinical trials targeting blood cancers.

Temas Resources has confirmed its patented Regenerative Chloride Leach (RCL) technology can produce commercial-grade titanium dioxide with significant cost reductions, positioning the company for global licensing opportunities.